Surgical Revascularization Outcomes After Oral Anticoagulation or Antiplatelets

• Status: Unknown status
• Trial end date: 2020-12-31
• Target enrollment: 0
• Participant gender: All

Summary

The primary purpose of this study is to evaluate whether treatment with oral anticoagulation or oral anticoagulation and aspirin is better than aspirin alone in cardiovascular outcomes and saphenous graft patency in patients submitted to coronary artery bypass graft.

• Phase: Phase 3
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Centro Hospitalar e Universitário de Coimbra, E.P.E.
• Treatments: Rivaroxaban

Criteria

Inclusion Criteria:

• Patients referred to coronary artery bypass graft and at least one saphenous vein graft

Exclusion Criteria:

• Need for dual antiplatelet therapy, other non-aspirin antiplatelet therapy or oral anticoagulant therapy

• Stroke within 1 month or any history of hemorrhagic or lacunar stroke

• Estimated glomerular filtration rate (eGFR)<15 mL/min